PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family by Olgiati, S. (Simone) et al.
ORIGINAL ARTICLE
PARK20 caused by SYNJ1 homozygous Arg258Gln mutation
in a new Italian family
Simone Olgiati & Anna De Rosa & Marialuisa Quadri & Chiara Criscuolo &
Guido J. Breedveld & Marina Picillo & Sabina Pappatà & Mario Quarantelli &
Paolo Barone & Giuseppe De Michele & Vincenzo Bonifati
Received: 24 April 2014 /Accepted: 25 April 2014 /Published online: 10 May 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract SYNJ1 has been recently identified by two inde-
pendent groups as the gene defective in a novel form of
autosomal recessive, early-onset atypical parkinsonism
(PARK20). Two consanguineous families were initially re-
ported (one of Sicilian and one of Iranian origins), with the
same SYNJ1 homozygous mutat ion (c.773G >A,
p.Arg258Gln) segregating with a similar phenotype of early-
onset parkinsonism and additional atypical features. Here, we
report the identification of the same SYNJ1 homozygous
mutation in two affected siblings of a third pedigree. Both
siblings had mild developmental psychomotor delay, follow-
ed, during the third decade of life, by progressive parkinson-
ism, dystonia, and mild cognitive impairment. One sibling
suffered one episode of generalized seizures. Neuroimaging
studies revealed severe nigrostriatal dopaminergic defects,
mild striatal and very mild cortical hypometabolism. Treat-
ment with dopamine agonists and anticholinergics resulted in
partial improvements. Genetic analyses revealed in both sib-
lings the SYNJ1 homozygous c.773G>A (p.Arg258Gln) mu-
tation. Haplotype analysis suggests that the mutation has
arisen independently in this family and the Sicilian PARK20
family previously described by us, in keeping with the hy-
pothesis of a mutational hot spot. This is the third reported
family with autosomal recessive, early-onset parkinsonism
associated with the SYNJ1 p.Arg258Gln mutation. This work
contributes to the definition of the genetic and clinical aspects
of PARK20. This newly recognized form must be considered
in the diagnostic work-up of patients with early-onset atypical
parkinsonism. The presence of seizures might represent a red
flag to suspect PARK20.
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Introduction
The autosomal recessive, early-onset parkinsonism is highly
heterogeneous on both clinical and genetic levels. Mutations
in parkin, PINK1, and DJ-1 cause parkinsonism with a good
and prolonged response to dopaminergic therapy, and clini-
cally presenting as early-onset Parkinson’s disease. On the
contrary, mutations in ATP13A2, PLA2G6, FBXO7, and
DNAJC6 cause early-onset atypical parkinsonism, with poor
response to levodopa and additional clinical signs
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(oculomotor disturbances, dystonia, pyramidal signs, cogni-
tive decline) of variable severity [1].
SYNJ1 has been recently identified by us [2] and by an
independent group [3] as the gene defective in a novel form of
autosomal recessive, early-onset atypical parkinsonism. Two
consanguineous families were initially reported (one of Sicil-
ian and one of Iranian origins), with the same SYNJ1 homo-
zygous c.773G>A mutation (p.Arg258Gln) segregating with
early-onset atypical parkinsonism. This form has been desig-
nated as PARK20 (Online Mendelian Inheritance in Man,
OMIM, 615530). The SYNJ1 gene encodes synaptojanin-1,
a phosphoinositide phosphatase protein involved in the regu-
lation of post-endocytic recycling of synaptic vesicles. Here,
we report the identification of the same SYNJ1 homozygous
mutation in two affected siblings of a third pedigree, originat-
ing from the Campania region in Southern Italy.
Materials and methods
This study was approved by the appropriate institutional re-
view boards. Written informed consent was obtained from all
participants.
Clinical studies We studied one Italian pedigree originating
from Campania (Southern Italy) with two out of four siblings
affected by early-onset, atypical parkinsonism. There was no
known parental consanguinity (the parents originate from the
same district of Naples, where ~100,000 inhabitants are resid-
ing) and no history of neurological diseases in the previous
generations. We performed detailed neurological and neuro-
psychological evaluations, including: mini mental state exam-
ination (MMSE); Raven’s Coloured Progressive Matrices, for
the assessment of general intelligence and visuospatial abili-
ties; Spatial Span, for spatial short-termmemory; Verbal Span,
for verbal short-term memory; Rey’s 15-word immediate and
delayed recall and story recall, for verbal long-term memory;
Arrigoni-De Renzi test, for constructional skills; and Frontal
Assessment Battery (FAB), attentive matrices, and phonemic
verbal fluency test, for attention and executive functions.
Neuroimaging studies Brain MRI studies were carried out at
3 T (TRIO, Siemens Medical Solutions, Erlangen, Germany)
in one patient, acquiring 3D T1-weighted Gradient-echo vol-
ume with isotropic voxels, axial diffusion-weighted images,
and axial and coronal T2-weighted turbo spin-echo and fluid-
attenuated inversion recovery (FLAIR) images. In the other
patient, MRI was performed at 1.5 T (Achieva, Philips
Healthcare, Eindhoven, NL) acquiring axial conventional
spin-echo T1-weighted images, axial diffusion-weighted and
fluid-attenuated inversion recovery (FLAIR) images, and sag-
ittal and coronal T2-weighted turbo spin-echo images.
MRI images (3 T) obtained with the same protocols in the
patients of the previous family with SYNJ1 mutations
previously described by us [2] were also available for
comparison.
Brain SPECT studies were performed 4 h after an intrave-
nous injection of 185 MBq of [123I]FP-CIT (DaT-SCAN, GE-
Healthcare, Wauwatosa, WI), and thyroid blockade with oral
administration of Lugol’s solution. SPECT was performed
using a dual-headed camera (E. CAM, Siemens Medical
Systems, Hoffman Estates, IL). Images were reconstructed
using a Butterworth filter (cut-off 0.5, order 10) and corrected
for attenuation using Chang’s algorithm (μ=0.06 cm−1). Re-
gion of interest (ROI) analysis was performed using a tem-
plate of circular ROIs for caudate and putamen of right and left
hemispheres and a polygonal ROI for the occipital cortex [4].
The outcome measure was the specific-to-nondisplaceable
binding ratio, V3″ (ROI striatum—ROI occipital/ROI
occipital).
[18F] FDG-PET brain images were acquired for 15 min in
3D mode between 45 and 60 min after intravenous adminis-
tration of 213–250 MBq of [18F]fluorodeoxyglucose in rest-
ing state and eyes closed condition, using a whole body PET/
CT scanner (Discovery LS, GE Medical System, Milwaukee,
WI). Images were reconstructed with iterative reconstruction
(FORE-Iterative) and corrected for attenuation using the CT
scan. Outcome measure was the relative glucose metabolism.
Both SPECT and PET images were spatially normalized
in the Montreal Neurological Institute (MNI) space using
SPM2 (Wellcome Department of Imaging Neuroscience,
London, UK).
Genetic studies Genomic DNA was isolated from peripheral
blood with standard protocols. Sanger sequencing and Multi-
ple Ligation Probe Amplification (MLPA) kits P051 and P052
(MRC Holland, Amsterdam, The Netherlands) were used to
screen the known genes causing early-onset parkinsonism in
the affected family members (sequencing of all exons and
exon-intron boundaries of parkin, PINK1, DJ-1, ATP13A2,
PLA2G6, FBXO7, and DNAJC6, and exon dosage of SNCA,
parkin, PINK1, DJ-1, and ATP13A2). Genome-wide homo-
zygosity mapping was performed using Illumina
HumanOmniExpress BeadChip array data (730,525 SNPs at
a median distance of 2.1 kb). Samples from the two affected
siblings (NAPO-41 and NAPO-42) were included. Data were
analyzed using Nexus Copy Number, Discovery Edition,
Version 7 (BioDiscovery, El Segundo, CA). Direct sequenc-
ing of the SYNJ1 gene (MIM 604297) was performed using
the Sanger method, and primers and PCR protocols previously
described by us [2] (GenBank accession numbers
NM_003895.3 and NP_003886.3). Haplotype analysis of
the new family and the Sicilian family previously reported
by us with the same SYNJ1mutation [2] was performed using
in-house software and the program Haploview 4.2 [5].
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Results
Both affected siblings from the Naples family had mild delay
in reaching the child developmental milestones. During the
third decade of life, they developed progressive parkinsonism,
dystonia, and mild cognitive impairment. Videotapes of these
two patients, recorded at the time of our examination, are
available (video 1 and video 2).Moreover, the clinical features
in the patients of this family and in those of two families
previously reported with SYNJ1 mutations are summarized
in Table 1.
The first patient (NAPO-41) suffered during adolescence
one brief episode of loss of consciousness, which was not
otherwise characterized. He developed progressive slowness
of movements from the age of 28 years. At our neurological
examination, at the age of 31 years, he exhibited hypomimia,
monotone and slurred speech, mildly stopped posture, re-
duced arms swings when walking, oro-mandibular tremor,
axial and limb rigidity, bradykinesia, mild trunk dystonia with
left flexion, reduced postural reflexes at the pull test, and mild
supranuclear upward vertical gaze limitation (this feature be-
ing not present during all the examinations). The patient also
showed irritability, drooling, and dysphagia. Cerebellar and
pyramidal signs were absent. The UPDRS-III score was 42/
108. The neuropsychological evaluation revealed a normal
MMSE score (28/30), but abnormal performances in the tests
for verbal and spatial short-term memory, and those for im-
mediate and long-term verbal memory. The FAB score was at
the lower limits of the normal range.
His sister (NAPO-42) suffered one episode of generalized
tonic-clonic seizures at the age of 16 years. At the age of
26 years, she developed oro-mandibular and left limbs tremor,
and subsequently slowness of movements. At our neurologi-
cal examination, at the age of 27 years, she showed a masked
face, monotone and slurred speech, rest tremor in the left
limbs and the right arm, limb rigidity, bradykinesia, mildly
flexed posture, slow gait with reduced arm swings, and re-
duced postural reflexes. The knee deep tendon reflexes were
brisk. The UPDRS-III score was 32/108. The patient also
complained of diffuse muscular pain. The neuropsychological
evaluation revealed a low, but still normal MMSE score (25/
30), and abnormal performances in the tests of verbal long and
short-term memory. The scores of the Raven’s Coloured Pro-
gressive Matrices and FAB were below the normal values.
The performance at the attentive matrices and phonemic ver-
bal fluency resulted at the lower limits of the normal range.
In both siblings, the blood chemistry, serum ceruloplasmin,
ferritin, and copper levels were normal. The Filipin test,
performed to exclude the Niemann Pick disease type C, was
negative. Levodopa was never administered to these siblings,
neither as acute challenge, nor as a chronic treatment. In the
affected brother (NAPO-41), the administration of
pramipexole up to 3 mg/day resulted in partial improvement Ta
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of the parkinsonism signs. Treatment of the affected sister
(NAPO-42) with the same dosage of pramipexole and
biperiden 2 mg twice a day improved tremor and bradykinesia
remarkably. In this patient, muscular pain was successfully
treated with duloxetine 30 mg once a day.
SPECT studies revealed in both patients a marked decrease
of dopamine transporter density in the whole striatum, which
was almost symmetric and more marked in the putamen
(Fig. 1d and e). Compared to controls, V3″ was reduced by
about 75–85% in the putamen and by 50–70% in the caudate.
FDG-PETstudies (Fig. 1a, b, and Suppl. Fig. 1) showed only a
verymild relative bilateral hypometabolism in the orbito-basal
frontal and temporo-parietal cortices and in the striatum in
NAPO-42, and in the caudate in NAPO-41. Brain MRI
showed no atrophy or focal abnormalities at the level of the
cerebral cortex, basal ganglia, midbrain, and hippocampus
(Suppl. Fig. 2). In both patients, the cerebellar dentate nuclei
appeared slightly hypointense in the T2-weighted echo-planar
images acquired within the diffusion sequence. This
finding, which remains of uncertain pathophysiologic sig-
nificance, was detected also in the patients of the Sicilian
family with SYNJ1 mutations, previously reported by us
(Suppl. Fig. 3).
The screening of the known genes causing early-onset
parkinsonism revealed in both NAPO-41 and NAPO-42 pa-
tients a single heterozygous mutation in PARK2 (c.1204C>T,
p.Arg402Cys). Genome-wide SNP-based mapping revealed a
2.7-Mb homozygous region on chromosome 21 (flanked by
the rs2833664 and rs2834651 markers), which include the
SYNJ1 gene (Fig. 2). Sanger sequencing of SYNJ1 exons
and exon-intron boundaries revealed a c.773G>A
(p.Arg258Gln) mutation, which was homozygous in both
affected siblings, and heterozygous in the unaffected parents
and one unaffected sib. DNAwas not available from the other
unaffected sib. Haplotype analysis of the SYNJ1 locus in the
patients from this novel family and those from the Sicilian
family previously described by us [2] revealed several discor-
dant SNPs, including intragenic SNPs and SNPs in the
flanking regions (the minimum distance from the mutation
being 4,723 bp) (Fig. 2); these comprise SNPs falling within
the same haplotype block of the mutation (Suppl. Fig. 4). This
scenario suggests that a common ancestor is unlikely, and the
SYNJ1 mutation has arisen independently in the ancestors of
these two Italian families.
Discussion
Here, we report the identification of a third family with early-
onset parkinsonism associated with the same homozygous
SYNJ1 mutation. This work supports further that SYNJ1 mu-
tations cause this newly recognized form of neurodegenera-
tive disease (PARK20), but also contributes to the definition
of its genetic and clinical features. Our haplotype analysis
suggests that a common ancestor is unlikely, and the SYNJ1
p.Arg258Gln mutation has arisen independently in these two
Fig. 1 Neuroimaging findings.
Brain metabolic activity using
[18F]fluorodeoxyglucose and
positron emission tomography
(PET) at the level of the basal
ganglia in NAPO-41 (a),
NAPO-42 (b), and a control
subject (c). Slight
hypometabolism is evident in the
striatum of patient NAPO-42 (b),
particularly the caudate nuclei,
and in the caudate of patient
NAPO-41 (a). Brain dopamine
transporter density values (V3″)
using single photon emission
computed tomography (DaT-
SCAN-SPECT) in NAPO-41 (d),
NAPO-42 (e), and a control
subject (f). Axial parametric
images show a marked
presynaptic nigrostriatal
dopaminergic deficit in both
patients
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Italian families. This, in turn, suggests that the guanine in
position 773 of the coding region of SYNJ1 is a mutational
hotspot. The interpretation of the heterozygous parkin
p.Arg402Cys mutation, present in both the Naples siblings
with PARK20, remains difficult. We have not identified a
second, compound heterozygous mutation in parkin. Further-
more, the pathogenicity of this variant has never been proven
and several studies reported it in patients as well as in controls
[6–8]. This variant might be a disease-unrelated coincidental
finding; however, we cannot exclude that it might have played
a role in the disease pathogenesis, together with the primary,
causative SYNJ1 mutations.
In all the PARK20 patients reported so far (n=6), the first
symptoms of parkinsonism developed during the third decade
of life (Table 1). Atypical signs of various degrees and types
have been observed in all these subjects; of note, the response
to levodopa was poor, and limited by the development of
severe and disabling dyskinesias, dystonias, or postural hypo-
tension. The two patients reported here for the first time have
had parkinsonism for only one and three years, respectively,
and have not been exposed to levodopa so far, offering there-
fore a window into the early phases of this newly-identified
form of Mendelian neurodegenerative disorder. However, a
wide phenotypic variability is emerging, which can only in
part be explained by the different disease duration. It is also
likely that the identification of additional patients with this
form will further expand the phenotypic and mutational
spectra.
From the clinical standpoint, PARK20 must be considered
in the diagnostic work-up of patients with early-onset atypical
parkinsonism. Of note, seizures have been reported in some of
these patients (Table 1), as well as in some with PARK19,
another recently identified form of early-onset parkinsonism,
caused by mutations in the gene DNAJC6 (OMIM 608375)
The protein product of this latter gene, auxilin-1, is a direct
functional partner of synaptojanin-1 during the process of
uncoating of the synaptic vesicles. The presence of seizures
might therefore be a red flag for suspecting one of these two
forms (PARK19, PARK20).
The identification of SYNJ1 mutations in PARK20 points
to defective post-endocytic recycling of synaptic vesicles in
the pathogenesis of neurodegeneration. Abnormalities at the
same level have been implicated in other forms of genetic
parkinsonism, such as those caused by mutations in LRRK2
[9], parkin [10], SNCA [11, 12], VPS35 [13, 14], andDNAJC6
[15, 16], suggesting that an abnormal recycling of synaptic
vesicles is a central theme in the pathogenesis. Therefore,
elucidating further the molecular mechanisms of PARK20
might also foster our understanding of the more common
forms of Parkinson’s disease.
rs2833930rs2833929
rs11702774
rs56238975 rs2833936
rs2254562 rs76502784
rs648648
33.8 33.9 34.0 34.1 34.2 34.3
Genomic position (Mb)
*
= c.773G>A p.Arg258Gln
SYNJ1 PAXBP1 C21orf62
C21orf59TCP10L
EVA1C
SYNJ1
Genomic position (Mb)
*
a
b
27 28 29 30 31 32 33 34 35 36
NAPO-41
NAPO-42
NAPO-16
NAPO-17
Fig. 2 Homozygosity mapping and haplotype analysis of the SYNJ1
locus. a Homozygosity map of the chromosome 21 in the patients from
this family (NAPO-41 and NAPO-42) and in those from the Sicilian
family with SYNJ1 mutations previously reported by us (NAPO-16 and
NAPO-17) [2]. Homozygous SNPs are depicted in orange, heterozygous
SNPs in blue; the position of the SYNJ1 gene is indicated. The
homozygous regions are highlighted in each patient by horizontal bars.
bHaplotype analysis of the SYNJ1 locus reveals several discordant SNPs
between the two families with the SYNJ1mutation. Only discordant SNPs
are shown; for the SNPs located within the SYNJ1 gene, RS codes are
shown; the position of the c.773G>A (p.Arg258Gln) mutation is indi-
cated with a red asterisk
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